Ronit Simantov
Chief Tech/Sci/R&D Officer presso GAMIDA CELL LTD.
Patrimonio netto: 18 455 $ in data 31/03/2024
Profilo
Ronit Simantov is currently the Director at TempestTx, Inc., Independent Director at Tempest Therapeutics, Inc., and Chief Medical & Scientific Officer at Gamida Cell Ltd.
Previously, Dr. Simantov held positions such as Oncology Director at Bayer HealthCare Pharmaceuticals, Inc., Independent Director at Clovis Oncology, Inc., Vice President-Clinical Research at OSI Pharmaceuticals, Inc., Vice President-Oncology Global Medical Affairs at Pfizer Inc., and Vice President-Medical Development at CuraGen Corp.
Dr. Simantov obtained an undergraduate degree from The Johns Hopkins University and a doctorate degree from New York University School of Medicine.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
GAMIDA CELL LTD.
0.39% | 15/03/2024 | 512 636 ( 0.39% ) | 18 455 $ | 31/03/2024 |
| 15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Ronit Simantov
| Società | Posizione | Inizio |
|---|---|---|
| GAMIDA CELL LTD. | Chief Tech/Sci/R&D Officer | 01/07/2017 |
| TEMPEST THERAPEUTICS, INC. | Director/Board Member | 06/08/2021 |
TempestTx, Inc.
 TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Director/Board Member | - |
Precedenti posizioni note di Ronit Simantov
| Società | Posizione | Fine |
|---|---|---|
| CLOVIS ONCOLOGY, INC. | Director/Board Member | 10/07/2023 |
| PFIZER, INC. | Corporate Officer/Principal | 01/06/2017 |
CuraGen Corp.
 CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Chief Tech/Sci/R&D Officer | 01/09/2009 |
Bayer HealthCare Pharmaceuticals, Inc.
 Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ. | Corporate Officer/Principal | 01/08/2007 |
| OSI PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Formazione di Ronit Simantov
| The Johns Hopkins University | Undergraduate Degree |
| New York University School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| TEMPEST THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
OSI Pharmaceuticals, Inc.
 OSI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OSI Pharmaceuticals, Inc. manufactured and develope dpharmaceutical drugs. The company was founded in 1983 and was headquartered in Farmingdale, NY. | Health Technology |
CuraGen Corp.
CuraGen Corp. Pharmaceuticals: MajorHealth Technology CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT. | Health Technology |
TempestTx, Inc.
TempestTx, Inc. BiotechnologyHealth Technology TempestTx, Inc. is a clinical stage biotechnology company which engages in advancing small molecule therapeutics that modulate anti-tumor pathways. The company is headquartered in South San Francisco, CA. | Health Technology |
Bayer HealthCare Pharmaceuticals, Inc.
Bayer HealthCare Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Bayer HealthCare Pharmaceuticals, Inc. manufactures pharmaceutical drugs. It offers pharmaceuticals and therapeutics in the areas of diagnostic imaging, hematology and cardiology, cancer, women's health and several other chronic diseases such as multiple sclerosis and Parkinson's disease. Bayer HealthCare Pharmaceuticals was founded in 1979 and is located in Wayne, NJ. | Health Technology |
Clovis Oncology, Inc.
 Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- Ronit Simantov
